Pace F, Sangaletti O, Bianchi Porro G
Divisione di Gastroenterologia, Ospedale L. Sacco, Milano, Italy.
Ital J Gastroenterol. 1990 Feb;22(1):28-32.
Many clinical trials on the effects of H2-antagonist drugs on reflux oesophagitis have shown unsatisfactory healing rates after conventional therapy, i.e. 4 to 12-week administration of 400 or 150mg bd of cimetidine or ranitidine, respectively. In order to verify if longer periods of treatment and/or higher dosage of drug can increase the healing rate, we performed a single-center double blind trial of 12 to 24 week duration on 75 patients with erosive/ulcerative reflux oesophagitis, comparing two ranitidine regimens, 150 vs 300mg bd. Patients who were healed after this period entered a 12 month maintenance treatment with half the dose previously received, i.e. 150 vs 300mg at bedtime. Our results show that, with both dosages, prolongation of acute treatment from 12 to 24 weeks allows complete additional healing of almost one fourth of patients. Furthermore, the data show that, both in the short and long-term treatment of reflux oesophagitis, conventional doses of ranitidine are as effective as double doses.
许多关于H2拮抗剂药物对反流性食管炎疗效的临床试验表明，常规治疗（即分别给予西咪替丁400mg每日两次或雷尼替丁150mg每日两次，持续4至12周）后的愈合率并不理想。为了验证延长治疗时间和/或增加药物剂量是否能提高愈合率，我们对75例糜烂性/溃疡性反流性食管炎患者进行了一项为期12至24周的单中心双盲试验，比较两种雷尼替丁治疗方案，即150mg每日两次与300mg每日两次。在此期间治愈的患者进入为期12个月的维持治疗，剂量为之前的一半，即睡前服用150mg与300mg。我们的结果表明，两种剂量下，将急性治疗从12周延长至24周可使近四分之一的患者完全额外愈合。此外，数据显示，在反流性食管炎的短期和长期治疗中，常规剂量的雷尼替丁与双倍剂量一样有效。
